Menu Search
Equities

Neuropace Inc

NPCE:NMQ

Neuropace Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)9.70
  • Today's Change0.70 / 7.78%
  • Shares traded67.03k
  • 1 Year change+11.62%
  • Beta1.8925
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Neuropace Inc grew revenues 43.72% from 45.52m to 65.42m while net income improved from a loss of 47.08m to a smaller loss of 32.96m.
Gross margin73.83%
Net profit margin-36.74%
Operating margin-30.17%
Return on assets-28.72%
Return on equity-214.55%
Return on investment-33.44%
More ▼

Cash flow in USDView more

In 2023, Neuropace Inc increased its cash reserves by 170.25%, or 11.45m. Cash Flow from Investing totalled 23.03m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 19.70m for operations while cash generated from financing totalled 8.13m.
Cash flow per share-0.9824
Price/Cash flow per share--
Book value per share0.3299
Tangible book value per share0.3299
More ▼

Balance sheet in USDView more

Neuropace Inc has a Debt to Total Capital ratio of 85.78%, a lower figure than the previous year's 341.56%.
Current ratio5.59
Quick ratio4.77
Total debt/total equity6.03
Total debt/total capital0.8578
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.